Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-21
2008-12-30
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S256000, C514S269000, C514S272000, C514S275000, C514S227800, C514S252130, C544S317000, C544S320000, C544S336000, C544S059000, C544S111000
Reexamination Certificate
active
07470685
ABSTRACT:
This invention features pyrimidine compounds of formula (I):R1isin which one of Raand Rbis H or alkyl, and the other is aryl or heteroaryl optionally substituted with Rdand Rem; each of R2and R4is H; R3is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl; R5is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; X is NRc; Y is covalent bond, CH2, C(O), C═N—Rc, C═N—ORc, C═N—SRc, O, S, S(O), S(O2), or NRc; Z is N or CH; one of U and V is N, and the other is CRc; and W is O, S, S(O), S(O2), NRc, or NC(O)Rc; in which Rcis H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl; Rdis halogen, CN, alkyl, alkyloxy, alkylcarbonyl, alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, hydroxyalkyl, alkylamino, or alkylaminocarbonyl; Reis halogen, CN, hydroxyl, alkyl, aryl, heteroaryl, alkoxyl, aryloxyl, or heteroaryloxyl; and m is 0, 1, 2, 3, or 4. The pyrimidine compounds can be used to treat an IL-12 overproduction-related disorder (e.g., rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus).
REFERENCES:
patent: 6384032 (2002-05-01), Ono et al.
patent: 6660733 (2003-12-01), Sun et al.
patent: 6680315 (2004-01-01), Ono et al.
patent: 6693097 (2004-02-01), Ono et al.
patent: 6706264 (2004-03-01), Leonard et al.
patent: 6858606 (2005-02-01), Sun et al.
patent: 6958332 (2005-10-01), Sun et al.
patent: 7045517 (2006-05-01), Ono et al.
patent: 7067514 (2006-06-01), Ono et al.
patent: 2005/0282809 (2005-12-01), Ono et al.
patent: 2006/0025409 (2006-02-01), Ono et al.
patent: 2006/0030560 (2006-02-01), Sun et al.
patent: WO 00/62778 (2000-10-01), None
Trincheri , Current Opinion In Hematology 4: 59-66, 1997.
European Search Report dated Feb. 7, 2005.
Trincheri, G., “Function and Clinical Use of Interleukin-12”, Current Opinion in Hematology, 4: 59-66, 1997.
Mylari, et al., Sorbitol Dehydrogenase Inhibitors (SDIs): A New Potent, Enantiometric SDI, 4-[2-1-R-Hydroxy-ethyl)-pyrimidin-4yl]-piperazine-1-sulfonic Acid Dimethylamide, J. Med. Chem., vol. 44, 2001, pp. 2695-2700.
Arvanitis et al., Non-Peptide Corticotropin-Releasing Hormone Antagonist: Syntheses and Structure-Activity Relationships of 2-Anilinopyrimidines and -triazines, J. Med. Chem., vol. 42, 1999, pp. 805-818.
International Search Report dated Jun. 12, 2003.
Nishigaki et al. “Synthesis of Iminodipyrimidnies”, Tetrahedron Letters. 7:539-542 (1969).
Becher, et al., “Experimental Autoimmune Encephalitis and Inflammation in the Absence of Interleukin-12,” The Journal of Clinical Investigation, vol. 110, No. 4, pp. 493-497 (2002).
Maeyama, et al., “Attenuation of Bleomycin-induced Pheumopathy in Mice by Monoclonal Antibody to Interleukin-12,” Am J Physiol, Lung Cell Mol. Physiol. vol. 280, pp. L1128-L1137 (2001).
Kostik Elena
Ono Mitsunori
Sun Lijun
Wada Yumiko
Balasubramanian Venkataraman
Edwards Angell Palmer & & Dodge LLP
Hsi Jeffrey D.
Russett Mark D.
Synta Pharmaceuticals Corp.
LandOfFree
Pyrimidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4039911